18889881171
Kalkine 0
countryflagUS
Logi

AAPL 179.46 -1.1022% MSFT 361.16 0.9221% NVDA 99.8699 2.2838% GOOGL 147.7072 0.6523% GOOG 149.84 0.402% AMZN 175.8608 0.3428% META 519.62 0.6528% AVGO 161.55 4.8073% LLY 733.0192 1.2835% TSLA 232.8325 -0.1961% TSM 145.8853 -0.1948% V 317.355 1.6121% JPM 221.4275 3.2585% UNH 554.49 5.6775% NVO 62.055 -2.4906% WMT 84.375 0.6501% LVMUY 112.12 0.7186% XOM 103.0 0.0583% LVMHF 563.0 0.8961% MA 490.7 1.0669%
AAPL 179.46 -1.1022% MSFT 361.16 0.9221% NVDA 99.8699 2.2838% GOOGL 147.7072 0.6523% GOOG 149.84 0.402% AMZN 175.8608 0.3428% META 519.62 0.6528% AVGO 161.55 4.8073% LLY 733.0192 1.2835% TSLA 232.8325 -0.1961% TSM 145.8853 -0.1948% V 317.355 1.6121% JPM 221.4275 3.2585% UNH 554.49 5.6775% NVO 62.055 -2.4906% WMT 84.375 0.6501% LVMUY 112.12 0.7186% XOM 103.0 0.0583% LVMHF 563.0 0.8961% MA 490.7 1.0669%

Cogent Biosciences Inc

Healthcare US COGT

4.375USD
-0.205(4.48%)

Last update at 2025-04-08T16:46:00Z

Day Range

4.375.11
LowHigh

52 Week Range

3.6713.50
LowHigh

Fundamentals

  • Previous Close 4.58
  • Market Cap785.94M
  • Volume508300
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-224.95699M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -121.62700M
  • Diluted EPS TTM-2.49

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-120M-100M-80M-60M-40M-20M0M20M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M20M40M60M80M100M120M140M160M180M200M220M240M260M280M300M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-60M-40M-20M0M20M40M60M80M100M120M140M160M180M200M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-120M-110M-100M-90M-80M-70M-60M-50M-40M-30M

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -140.24100M -72.27300M -74.80800M -31.83300M -34.53200M
Minority interest - - - - -
Net income -132.64300M -71.80600M -66.45100M -30.27300M -34.53200M
Selling general administrative 26.21M 19.64M 17.42M 10.97M 7.45M
Selling and marketing expenses - - - - -
Gross profit - - 7.87M 22.50M 9.73M
Reconciled depreciation 5.88M 0.15M 0.72M 1.29M 1.32M
Ebit -153.71700M -75.55100M -82.19900M -33.47100M -36.00500M
Ebitda -147.83900M -75.40400M -89.69200M -32.17800M -34.68400M
Depreciation and amortization 5.88M 0.15M -7.49300M 1.29M 1.32M
Non operating income net other 7.60M 3.28M 7.39M - -
Operating income -147.83900M -75.55100M -82.19900M -32.17800M -36.00500M
Other operating expenses 147.84M 75.55M 90.07M 54.68M 45.74M
Interest expense 3.99M 3.13M 0.14M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 3.99M 0.47M 0.14M 0.27M 1.15M
Net interest income 3.99M 0.47M 0.14M 0.27M 1.15M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -7.59800M -0.46700M -8.35700M -1.56000M 1.47M
Total revenue 0.00000M 0.00000M 7.87M 22.50M 9.73M
Total operating expenses 147.84M 75.55M 90.07M 54.68M 45.74M
Cost of revenue - - - - -
Total other income expense net 7.60M 3.28M 7.39M 0.34M 0.32M
Discontinued operations - - - - -
Net income from continuing ops -140.24100M -72.27300M -74.80800M -31.83300M -34.53200M
Net income applicable to common shares -140.24100M -72.27300M -179.20800M -31.83300M -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 313.44M 300.81M 232.09M 250.92M 49.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.06M 5.69M 2.95M 2.72M 1.17M
Total liab 55.63M 45.08M 17.91M 16.25M 17.66M
Total stockholder equity 257.80M 255.74M 214.18M 234.67M 31.76M
Deferred long term liab - - - - -
Other current liab 0.44M 17.88M 3.29M 6.51M 7.13M
Common stock 0.09M 0.07M 0.04M 0.03M 0.03M
Capital stock 60.12M 65.90M 85.44M 110.91M 0.03M
Retained earnings -603.62400M -411.21400M -270.97300M -198.70000M -123.89200M
Other liab - - - - -
Good will - - - - -
Other assets - 4.75M 4.98M 5.87M 1.68M
Cash 53.23M 139.89M 219.68M 242.19M 37.42M
Cash and equivalents - - - - -
Total current liabilities 38.17M 26.85M 17.08M 13.09M 13.25M
Current deferred revenue 25.69M 1.70M 7.97M 3.79M 1.31M
Net debt -34.37600M -120.23700M -216.52900M -236.98300M -31.39200M
Short term debt 1.39M 1.42M 2.32M 2.05M 1.62M
Short long term debt - - - - -
Short long term debt total 18.85M 19.65M 3.15M 5.21M 6.03M
Other stockholder equity 801.06M 601.15M 399.71M 322.45M 155.62M
Property plant equipment - 7.78M 1.71M 4.75M 7.15M
Total current assets 270.77M 264.97M 222.63M 244.91M 40.59M
Long term investments 7.46M - - - -
Net tangible assets - 189.91M 128.78M 123.79M 31.76M
Short term investments 212.48M 119.39M - - 0.00000M
Net receivables - - - 0.00000M 2.00M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 10.65M 5.84M 3.48M 0.73M 3.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.25M -0.10400M - - -4.63100M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.04M 0.03M 0.03M
Preferred stock total equity - 65.83M 85.40M 110.88M -
Retained earnings total equity - -411.21400M -270.97300M -198.70000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.86M 4.75M 4.98M 1.25M 1.68M
Deferred long term asset charges - - - - -
Non current assets total 42.67M 35.84M 9.46M 6.00M 8.83M
Capital lease obligations 18.85M 19.65M 3.15M 5.21M 6.03M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -117.85500M -1.71900M 8.42M 23.16M -10.53100M
Change to liabilities 11.95M 6.18M -3.76600M -14.97000M -
Total cashflows from investing activities -124.71800M -1.71900M 8.42M 23.16M -
Net borrowings - - - - -
Total cash from financing activities 163.56M 37.98M 232.20M 0.11M 70.35M
Change to operating activities -1.60800M -0.73100M -3.55000M 1.22M -
Net income -140.24100M -72.27300M -74.80800M -31.83300M -34.53200M
Change in cash -79.79800M -22.50600M 204.77M -18.24700M 27.33M
Begin period cash flow 220.94M 243.44M 38.68M 56.93M 29.60M
End period cash flow 141.14M 220.94M 243.44M 38.68M 56.93M
Total cash from operating activities -118.63800M -58.76300M -35.85000M -41.51400M -32.48900M
Issuance of capital stock 161.94M 38.01M 231.64M 0.00000M 71.79M
Depreciation 5.88M 0.15M 0.72M 1.29M 1.32M
Other cashflows from investing activities - - 8.10M 8.10M -
Dividends paid - - - - -
Change to inventory - - -3.55000M 1.22M 2.21M
Change to account receivables - 0.00000M 2.00M -0.33200M -0.83800M
Sale purchase of stock 1.61M 0.06M 124.47M - -
Other cashflows from financing activities 1.61M -0.03000M 99.47M 0.11M -1.44700M
Change to netincome 18.37M 11.69M 43.55M 3.11M -
Capital expenditures 6.86M 1.72M 0.32M 0.03M 0.55M
Change receivables - - 2.00M - -
Cash flows other operating -7.91400M -4.50500M -2.29600M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -79.79800M -22.50600M 204.77M - -
Change in working capital 0.75M 2.02M -5.31600M -14.08400M -2.15300M
Stock based compensation 18.37M 11.69M 6.02M 3.24M 3.09M
Other non cash items -3.39400M -0.34300M 45.03M -0.13100M 0.02M
Free cash flow -125.50100M -60.48200M -35.85000M -41.54700M -33.03800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COGT
Cogent Biosciences Inc		 -0.205 4.48% 4.38 - - 1320.63 3.15 925.41 -2.1297
NVO
Novo Nordisk A/S		 -1.585 2.49% 62.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.59 0.93% 62.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.025 0.0053% 474.54 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.395 1.64% 563.38 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Cogent Biosciences Inc

275 Wyman Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Andrew R. Robbins M.B.A. Pres, CEO & Director 1976
Dr. John Edward Robinson Ph.D. Chief Scientific Officer NA
Dr. Jessica Sachs M.D. Chief Medical Officer 1975
Mr. John L. Green C.A., CPA CFO & Principal Accounting Officer 1980
Mr. Brad Barnett Chief Technology Officer NA
Mr. Evan D. Kearns J.D. Chief Legal Officer & Corp. Sec. 1980
Ms. Erin Schellhammer Chief People Officer NA
Ms. Sara Saltzman Sr. VP of Regulatory Affairs NA
Mr. Dana R. Martin Pharm.D. Sr. VP of Medical Affairs & Chief Patient Officer NA
Brad Fell VP & Head of Medicinal Chemistry NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.